Bank of America’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

Bank of America’s Portfolio GNRX Stock Details GNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,000	Closed	-$24K	–	7612
2018 Q1	$24K	Hold	1,000	–	–	﹤0.01%	6332
2017 Q4	$24K	Hold	1,000	–	–	﹤0.01%	6367
2017 Q3	$22K	Buy	+1,000	New	+$22.1K	﹤0.01%	6244

Other funds holding GNRX

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of America's GNRX Position: Q2 2018 in Review

Bank of America sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q2 2018, closing a stake of 1,000 shares — an estimated $24K sold.

Bank of America first reported a position in GNRX in Q3 2017 and held it in 3 quarters. The position peaked at $24K in Q1 2018. 1 fund tracked by Wall St. Rank holds GNRX as of Q2 2018.

Bank of America reported no remaining VanEck Vectors Generic Drugs ETF position as of Q2 2018 after selling out during the quarter.
Bank of America sold 1,000 VanEck Vectors Generic Drugs ETF shares in Q2 2018, an estimated $24K.
Bank of America first reported a position in VanEck Vectors Generic Drugs ETF in Q3 2017 and held it in 3 quarters.
Bank of America's VanEck Vectors Generic Drugs ETF position peaked at $24K in Q1 2018.
1 fund tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q2 2018.

Based on Bank of America's 13F filing for Q2 2018, filed 14 Aug 2018.